Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice

Blood

Volumn 121, Issue 24, 2013, Pages 4938-4947

  Morowski, Martina ^a   Vögtle, Timo ^a   Kraft, Peter ^b   Kleinschnitz, Christoph ^b   Stoll, Guido ^b   Nieswandt, Bernhard ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA THROMBOSIS; ARTERIOLE; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BRAIN INFARCTION; BRAIN ISCHEMIA; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; HEMOSTASIS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ANIMAL; AORTA; BLOOD; CAROTID ARTERY; CEREBROVASCULAR ACCIDENT; DISEASE MODEL; METABOLISM; PATHOLOGY; THROMBOCYTE; THROMBOSIS;

ANIMALS; AORTA; BLOOD PLATELETS; CAROTID ARTERIES; DISEASE MODELS, ANIMAL; HEMORRHAGE; MICE; PLATELET COUNT; STROKE; THROMBOCYTOPENIA; THROMBOSIS;

MLCS; MLOWN;

EID: 84881298567     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-10-461459     Document Type: Article

References (50)

1. Jackson SP. Arterial thrombosis - insidious, unpredictable and deadly. Nat Med. 2011;17(11):1423-1436.
2. Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood. 2008;112(9):3555-3562.
3. Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica. 2010;95(7):1167-1175.
4. Chong BH, Ho SJ. Autoimmune thrombocytopenia. J Thromb Haemost. 2005;3(8):1763-1772. (Pubitemid 41716563)
5. George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology (Am Soc Hematol Educ Program). 2009;2009(1):153-158.
6. Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med. 2009;133(2):309-314.
7. Andres E, Dali-Youcef N, Serraj K, Zimmer J. Recognition and management of drug-induced cytopenias: the example of idiosyncratic drug-induced thrombocytopenia. Expert Opin Drug Saf. 2009;8(2):183-190.
8. Prasad HK, Kaushal V, Mehta P. Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: case report and review of literature. Am J Hematol. 2007;82(9):855-857. (Pubitemid 350194523)
9. Passos AM, Treitinger A, Spada C. An overview of the mechanisms of HIV-related thrombocytopenia. Acta Haematol. 2010;124(1):13-18.
10. Louie KS, Micallef JM, Pimenta JM, Forssen UM. Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review. J Viral Hepat. 2011;18(1):1-7.
11. Pham A, Wang J. Bernard-Soulier syndrome: an inherited platelet disorder. Arch Pathol Lab Med. 2007;131(12):1834-1836. (Pubitemid 350294586)
12. Nurden AT, Nurden P. The gray platelet syndrome: clinical spectrum of the disease. Blood Rev. 2007;21(1):21-36. (Pubitemid 46097190)
13. Ochs HD. Mutations of the Wiskott-Aldrich Syndrome Protein affect protein expression and dictate the clinical phenotypes. Immunol Res. 2009;44(1-3):84-88.
14. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207.
15. Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001;19(4):1137-1146. (Pubitemid 32176291)
16. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-186.
17. Ambler KL, Vickars LM, Leger CS, et al. Clinical features, treatment, and outcome of HIV-associated immune thrombocytopenia in the HAART era. Adv Hematol. 2012;2012:910954.
18. Eberl W, Dickerhoff R; Pediatric Committee of Society of Thrombosis and Hemostasis Research. Newly diagnosed immune thrombozytopenia - German guideline concerning initial diagnosis and therapy. Klin Padiatr. 2012;224(3):207-210.
19. Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P, Barbui T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood. 1991;77(1):31-33.
20. Lakshmanan S, Cuker A. Contemporary management of primary immune thrombocytopenia in adults. J Thromb Haemost. 2012;10(10):1988-1998.
21. Iyori H, Bessho F, Ookawa H, et al; Japanese Study Group on childhood ITP. Intracranial hemorrhage in children with immune thrombocytopenic purpura. Japanese Study Group on childhood ITP. Ann Hematol. 2000;79(12):691-695.
22. Stanworth SJ, Turner DM, Brown J, et al. Major histocompatibility complex susceptibility genes and immune thrombocytopenic purpura in Caucasian adults. Hematology. 2002;7(2):119-121. (Pubitemid 34692997)
23. Nomura S, Matsuzaki T, Ozaki Y, et al. Clinical significance of HLA-DRB1*0410 in Japanese patients with idiopathic thrombocytopenic purpura. Blood. 1998;91(10):3616-3622. (Pubitemid 28225727)
24. Bettaieb A, Fromont P, Louache F, Oksenhendler E, Vainchenker W, Duédari N, Bierling P. Presence of cross-reactive antibody between human immunodeficiency virus (HIV) and platelet glycoproteins in HIV-related immune thrombocytopenic purpura. Blood. 1992;80(1):162-169.
25. Pockros PJ, Duchini A, McMillan R, Nyberg LM, McHutchison J, Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 2002;97(8):2040-2045.
26. Domínguez V, Govezensky T, Gevorkian G, Larralde C. Low platelet counts alone do not cause bleeding in an experimental immune thrombocytopenic purpura in mice. Haematologica. 2003;88(6):679-687. (Pubitemid 36781595)
27. Goerge T, Ho-Tin-Noe B, Carbo C, et al. Inflammation induces hemorrhage in thrombocytopenia. Blood. 2008;111(10):4958-4964.
28. Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE, Zirngibl H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood. 2000;96(7):2520-2527.
29. Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J; ITP Study Group. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol. 2004;76(3):205-213. (Pubitemid 38828837)
30. Pleines I, Hagedorn I, Gupta S, et al. Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. Blood. 2012;119(4):1054-1063.
31. Grosse J, Braun A, Varga-Szabo D, et al. An EF hand mutation in Stim1 causes premature platelet activation and bleeding in mice. J Clin Invest. 2007;117(11):3540-3550. (Pubitemid 350097009)
32. Braun A, Varga-Szabo D, Kleinschnitz C, et al. Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation. Blood. 2009;113(9):2056-2063.
33. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17(3):472-476. (Pubitemid 16085691)
34. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007;115(17):2323-2330. (Pubitemid 46685900)
35. Bender M, Hagedorn I, Nieswandt B. Genetic and antibody-induced glycoprotein VI deficiency equally protects mice from mechanically and FeCl (3) -induced thrombosis. J Thromb Haemost. 2011;9(7):1423-1426.
36. Bergmeier W, Rackebrandt K, Schröder W, Zirngibl H, Nieswandt B. Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. Blood. 2000;95(3):886-893. (Pubitemid 30062710)
37. Tsakiris DA, Scudder L, Hodivala-Dilke K, Hynes RO, Coller BS. Hemostasis in the mouse (Mus musculus): a review. Thromb Haemost. 1999;81(2):177-188. (Pubitemid 29078299)
38. Alugupalli KR, Michelson AD, Barnard MR, Leong JM. Serial determinations of platelet counts in mice by flow cytometry. Thromb Haemost. 2001;86(2):668-671. (Pubitemid 32743283)
39. Karpatkin S, Khan Q, Freedman M. Heterogeneity of platelet function. Correlation with platelet volume. Am J Med. 1978;64(4):542-546. (Pubitemid 8322900)
40. Kleinschnitz C, De Meyer SF, Schwarz T, et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood. 2009;113(15):3600-3603.
41. Nieswandt B, Kleinschnitz C, Stoll G. Ischaemic stroke: a thrombo-inflammatory disease? J Physiol. 2011;589(Pt 17):4115-4123.
42. Neunert CE, Buchanan GR, Imbach P, et al; Intercontinental Childhood ITP Study Group Registry II Participants. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood. 2008;112(10):4003-4008.
43. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost. 1990;16(1):1-20. (Pubitemid 20049639)
44. Nørgaard M, Severinsen MT, Lund Maegbaek M, Jensen AO, Cha S, Sørensen HT. Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2012;159(1):109-111.
45. De La Peña A, Fareed J, Thethi I, Morales-Vidal S, Schneck MJ, Shafer D. Ischemic stroke in the setting of chronic immune thrombocytopenia in an elderly patient - a therapeutic dilemma. Clin Appl Thromb Hemost. 2012;18(3):324-326.
46. Gracia MC, Cebollero IC, Lezcano JS, Osuna GG, Miguel JA, Peralta LP. Invasive treatment performed for acute myocardial infarction in a patient with immune thrombocytopenic purpura. Int J Cardiol. 2008;127(3):e183-e185. (Pubitemid 351885118)
47. Nieswandt B, Bergmeier W, Schulte V, Rackebrandt K, Gessner JE, Zirngibl H. Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FcRgamma chain. J Biol Chem. 2000;275(31):23998-24002. (Pubitemid 30624690)
48. May F, Hagedorn I, Pleines I, et al. CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood. 2009;114(16):3464-3472.
49. Sachs UJ, Nieswandt B. In vivo thrombus formation in murine models. Circ Res. 2007;100(7):979-991. (Pubitemid 46598922)
50. Schwer HD, Lecine P, Tiwari S, Italiano JE Jr, Hartwig JH, Shivdasani RA. A lineage-restricted and divergent beta-tubulin isoform is essential for the biogenesis, structure and function of blood platelets. Curr Biol. 2001;11(8):579-586. (Pubitemid 32324760)